Pfizer Cash on Hand 2012-2026 | PFE | MacroTrends

Pfizer Cash on Hand 2012-2026 | PFE

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Pfizer cash on hand for the quarter ending March 31, 2026 was $14.984B, a 50.56% increase year-over-year.

Pfizer cash on hand for 2024 was $20.477B, a 61.36% increase from 2023.
Pfizer cash on hand for 2023 was $12.69B, a 44.18% decline from 2022.
Pfizer cash on hand for 2022 was $22.732B, a 26.83% decline from 2021.

Pfizer Cash on Hand 2012-2026 | PFE

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Pfizer cash on hand for 2024 was $20.477B, a 61.36% increase from 2023.
Pfizer cash on hand for 2023 was $12.69B, a 44.18% decline from 2022.
Pfizer cash on hand for 2022 was $22.732B, a 26.83% decline from 2021.

Related Stocks
Company Name	Market Cap
Eli Lilly (LLY)	$887.6B
Johnson & Johnson (JNJ)	$574.4B
AbbVie (ABBV)	$367.7B
Roche Holding AG (RHHBY)	$318.8B
Merck (MRK)	$299.9B
Novartis AG (NVS)	$294B
Novo Nordisk (NVO)	$167.5B
Sanofi (SNY)	$114B
Bayer (BAYRY)	$46.2B
Innoviva (INVA)	$1.8B